Processa (PCSA) strategy chief buys 1,369 shares at $2.97

Rhea-AI Filing Summary

Processa Pharmaceuticals, Inc. Chief Business - Strategy Officer Patrick Lin bought common stock in the open market. On April 15, 2026, he purchased 1,369 shares of Processa common stock at $2.97 per share. After this transaction, he directly holds 4,725 shares and indirectly holds 1,740 shares through the Lin Family Trust dated February 4, 2024.

Insider Trade Summary

Net Buyer: 1,369 shares ($4,066)

Net Buy 2 txns

Insider Lin Patrick

Role Chief Business - Strategy Off

Bought 1,369 shs ($4K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,369	$2.97	$4K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 4,725 shares (Direct); Common Stock — 1,740 shares (Indirect, Lin Family Trust Feb 4, 2024)

Footnotes (1)

Key Figures

Shares purchased: 1,369 shares Purchase price: $2.97 per share Direct holdings after: 4,725 shares +2 more

5 metrics

Shares purchased 1,369 shares Open-market purchase of common stock on April 15, 2026

Purchase price $2.97 per share Price paid for Processa common stock

Direct holdings after 4,725 shares Direct ownership following the reported purchase

Indirect holdings 1,740 shares Held via Lin Family Trust dated February 4, 2024

Net buy direction Net-buy of 1,369 shares transactionSummary netBuySellShares and direction

Key Terms

open-market purchase, indirect ownership, Lin Family Trust Feb 4, 2024, Form 4

4 terms

open-market purchase financial

"transaction_action: "open-market purchase" for 1,369 common shares"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

indirect ownership financial

"direct_or_indirect: "I" with nature_of_ownership trust holding"

Lin Family Trust Feb 4, 2024 financial

"nature_of_ownership: "Lin Family Trust Feb 4, 2024""

Form 4 regulatory

"INSIDER FILING DATA (Form 4): transaction details for Patrick Lin"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lin Patrick

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FLORIDA 32960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business - Strategy Off

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/15/2026		P		1,369	A	$2.97	4,725	D
Common Stock								1,740	I	Lin Family Trust Feb 4, 2024

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Patrick Lin by John J. Wolfel, as Attorney-in-Fact	04/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did PCSA executive Patrick Lin report?

Patrick Lin reported an open-market purchase of Processa Pharmaceuticals common stock. He bought 1,369 shares at $2.97 per share, increasing his direct holdings to 4,725 shares and indirectly holding 1,740 shares through the Lin Family Trust dated February 4, 2024.

How many PCSA shares did Patrick Lin buy and at what price?

Patrick Lin bought 1,369 shares of Processa Pharmaceuticals common stock at $2.97 per share. This open-market purchase on April 15, 2026, increased his direct ownership and reflects additional personal exposure to the company’s equity beyond his existing direct and trust holdings.

What are Patrick Lin’s total direct PCSA shareholdings after the trade?

After the April 15, 2026 transaction, Patrick Lin directly holds 4,725 Processa Pharmaceuticals common shares. This figure excludes 1,740 additional shares held indirectly through the Lin Family Trust dated February 4, 2024, which are reported separately as indirect ownership in the filing.

Does Patrick Lin have indirect ownership of PCSA shares?

Yes. In addition to his direct holdings, Patrick Lin has indirect ownership of 1,740 Processa Pharmaceuticals common shares. These shares are held through the Lin Family Trust dated February 4, 2024, and are reported as indirect ownership separate from his directly held stock.

Was the PCSA insider transaction an open-market purchase or sale?

The reported Processa Pharmaceuticals insider transaction was an open-market purchase, not a sale. Patrick Lin bought 1,369 common shares at $2.97 each, resulting in net buying activity and raising his directly held position as disclosed in the Form 4 filing.